Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on August 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 113,750 shares of common stock to 14 new employees.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $9.95, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a trea
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
2. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
3. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
6. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Expands Senior Management Team
8. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
9. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
10. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
11. Trading Halted Today in Optimer Pharmaceuticals Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... YORK , LONDON , ... , May 20, 2013 ... of Osteoarthritis and Preference for Minimally Invasive Procedures to ... landscape, and market trends for the six arthroscopy device ... (FMSs), arthroscopy implants, arthroscopy radio frequency systems, and arthroscopy ...
(Date:5/20/2013)... announced today the presentation of results from a new ... among diabetic patients in the U.S. than previously recognized. ... both type 1 and type 2 diabetes, but this ... common type 2 disease. Lee ... Medicine at Harvard Medical School and Director of the ...
(Date:5/20/2013)... CHICAGO, Ill. , May 20, 2013 /PRNewswire/ ... the initiation of a Phase 3 clinical study ... to assess the effects of the investigational compound ... progression of kidney disease in patients with stage ... type 2 diabetes.  SONAR is a large, multinational, ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... Medical Tactile, Inc. and Valentus Medical Technologies, Inc. ... , Canada , has signed a partnership agreement with Medical Tactile, ... SureTouch™ , the non-invasive digital breast imaging technology, worldwide, with the ... , , ...
... July 13 Amira Pharmaceuticals, Inc. today announced that the ... Activating Protein (FLAP) Inhibitors," which includes coverage of Amira,s AM103 and ... , , ... , Amira and GlaxoSmithKline (GSK) entered into a worldwide exclusive agreement ...
Cached Medicine Technology:Partnership Brings Breast Image Documentation Technology to Women Around the World 2Amira Announces AM103 and AM803 Patent Grant in the United Kingdom 2
(Date:5/20/2013)... new Canadian study has uncovered an apparent gender bias ... men to get trauma center care following a severe ... services in general have been recognized for some time, ... the treatment of severe injuries in trauma centers," study ... Sciences Centre and the University of Toronto, said in ...
(Date:5/20/2013)... in Sweden have mapped the significance of heredity ... have previously examined whether different forms of the ... heart disease, ischemic stroke, peripheral arterial disease and ... and parents have suffered different types of cardiovascular ... highest for atherosclerosis of the aorta followed by ...
(Date:5/20/2013)... Plains, NY (PRWEB) May 20, 2013 ... firm of Levy Phillips & Konigsberg LLP ... Street in White Plains, New York. LPK will better ... in the Hudson Valley, including Westchester, Putnam, Rockland, Orange, ... helping families affected by asbestos-related diseases throughout New York, ...
(Date:5/20/2013)... as a consequence of diabetic foot ulcer that does ... this situation are very limited. In his doctoral thesis ... Department of Medical Biochemistry and Biophysics at Ume University ... may completely change the lives of millions of patients. ... chronic wounds that largely impair the quality of life ...
(Date:5/20/2013)... May 20, 2013 The producers of ... to the essentials of home schooling. It will educate viewers ... need to assist children in reaching educational goals. Most homes ... basic needs in education. Instructors can send tests to state ... the Web. The celebrity-hosted segment is a top-notch guide for ...
Breaking Medicine News(10 mins):Health News:Women Less Likely to Get Trauma Center Care After Injury: Study 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:Editions TV Presents a Home School Essentials Segment 2
... Support NIH Information Sharing and Collaboration ServicesCHANTILLY, Va., ... region,s leading providers of government professional technical solutions, ... by the National Institutes of Health (NIH) for ... February 18, 2009, covers a one year period ...
... 25 AdaptaVan, LLC has announced partnerships with ... of its customized wheelchair-accessible vans throughout ... Emmett Koelsch Coaches, Inc. of Oregon City, Ore.; ... Conn.; Superior Chevrolet, Inc. of Cincinnati, Ohio; Autotronics ...
... Cancer Center have developed an assay that may be ... a predisposition to cancer. , The study, published in ... done in yeast and mammalian cells. , Cancer cells ... Robert Schiestl, have discovered a mechanism that switches on ...
... LONDON, March 25 Clinica - the world,s leading medical,technology ... state of,asbestos regulation in the UK, in light of discrepancies ... Westminster. , On the day of ... latest developments in Clinica,s investigation into the extent,of the problem ...
... March 25 Abbott ( NYSE: ABT ) will announce ... before the market opens.The announcement will be followed by a ... Central time (9 a.m. Eastern), and will be accessible through ... An archived edition of the call will be available after ...
... Physicians Practice and Rose Medical Center have joined forces ... time to devote to patient care. This new partnership ... the Denver Metro Area better handle the cumbersome and ... new alliance, Rose Medical Center will use Physicians Practice,s ...
Cached Medicine News:Health News:NIH Awards Blanket Purchase Agreement (BPA) to Citizant 2Health News:AdaptaVan, LLC Expands National Availability of Wheelchair-Accessible Vans 2Health News:Discovery may result in new test to determine predisposition to cancer 2Health News:Discovery may result in new test to determine predisposition to cancer 3Health News:Westminster Safety Disagreement Highlights Risk in Schools 2Health News:Westminster Safety Disagreement Highlights Risk in Schools 3Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 2Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 3
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: